Advertisements



Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech

One of the three widely awaited clinical trial readouts from Gilead Sciences, Inc. (NASDAQ: GILD) turned out to be a disappointment, sending its shares down sharply Tuesday.  Latest Ratings for GILD.....»»

Category: blogSource: benzingaFeb 12th, 2019

Dash for NASH trips up Gilead, but "fatty liver disease" remains biotech target

A late-stage clinical trial by Gilead Sciences Inc. failed in fatty liver disease, the company said, sending a blow to a drug industry that has seen treatments for the disease as the next big thing. The Foster City-based company's (NASDAQ: GILD) s.....»»

Category: topSource: bizjournalsFeb 12th, 2019

"A Negative Inflection": Wells Fargo, Morgan Stanley React To NetApp"s Q3 Sales Miss, Weak Guidance

NetApp Inc. (NASDAQ: NTAP) shares were under pressure Thursday in reaction to third-quarter results released Wednesday after the market close that included a sales miss.  The Analysts.....»»

Category: earningsSource: benzingaFeb 14th, 2019

Gilead"s Failed NASH Drug Trial Drags Stock Lower

Gilead Sciences, Inc. (NASDAQ: GILD) is facing another setback, as its non-alcoholic steatohepatitis, or NASH, candidate Selonsertib flunked in a late-stage study. read more.....»»

Category: blogSource: benzingaFeb 12th, 2019

Aeglea Plunges On Updated Data For Arginase 1 Deficiency Candidate, Wells Fargo Downgrade

Shares of Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) were slumping Tuesday following the release of data from an early-to-mid- stage trial of its lead product c read more.....»»

Category: blogSource: benzingaSep 4th, 2018

AT&T suffers downgrade as analysts see "many balls to juggle" with Time Warner

AT&T might have the right plan with Time Warner and fresh video options, but a new analyst note says it’s going to take a lot to navigate that journey. Analysts at Wells Fargo downgraded shares of AT&T (NYSE: T) on Wednesday amid concerns about.....»»

Category: topSource: bizjournalsAug 23rd, 2018

"A Negative Inflection": Wells Fargo, Morgan Stanley React To NetApp"s Q3 Sales Miss, Weak Guidance

NetApp Inc. (NASDAQ: NTAP) shares were under pressure Thursday in reaction to third-quarter results released Wednesday after the market close that included a sales miss.  Latest Ratings f.....»»

Category: blogSource: benzingaFeb 14th, 2019

Analyst: Intercept"s NASH Drug Could Launch Sans Competition After Gilead Trial Failure

With Gilead Sciences, Inc. (NASDAQ: GILD)'s NASH setback, Intercept Pharmaceuticals, Inc. Latest Ratings for ICPT DateFirmActionFromT.....»»

Category: blogSource: benzingaFeb 13th, 2019

Viking seen as possible Gilead target after NASH treatment fails in late-stage trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 12th, 2019

Gilead downgraded to Market Perform from Outperform at Wells Fargo

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 11th, 2019

The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Her.....»»

Category: earningsSource: benzingaFeb 5th, 2019

Gilead price target lowered to $89 from $95 at Wells Fargo

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 5th, 2019

The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) read more.....»»

Category: blogSource: benzingaFeb 5th, 2019

The Sniff Test: Wells Fargo spent $7.3 billion to help buy an earnings beat — was it worth it?

The $7.3 billion Wells Fargo spent on share repurchases during the fourth quarter failed to prop up its stock price, but it effectively helped the bank one-up its blue-chip rival JPMorgan Chase & Co. with an earnings beat. Was it worth it?.....»»

Category: topSource: marketwatchJan 15th, 2019

Wells Fargo revenue misses on weakness in consumer banking

Wells Fargo & Co on Tuesday reported quarterly revenue that missed analysts' estimates, as revenue across all its banking units declined, especially at community banking, the unit at the center of its 2016 sales scandal......»»

Category: topSource: reutersJan 15th, 2019

Citigroup, JPMorgan, Wells Fargo, Goldman Sachs and Morgan Stanley are part of Zacks Earnings Preview

Zacks.....»»

Category: topSource: redinewsJan 14th, 2019

Citi Fixed Income Crashes 21%, Worst Since 2011, In Ominous Sign For Wall Street

While traditionally it is JPMorgan Chase that kicks off bank earnings season, this quarter, Citigroup is taking the spotlight with its just reported Q4 results (followed by JPMorgan and Wells Fargo & Co. on Tuesday), and.....»»

Category: blogSource: zerohedgeJan 14th, 2019

Wells Fargo financial analysts to hold an analyst/industry conference call

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 8th, 2019

The Tell: Why pension funds may be driving the stock market’s post-Christmas bounce

Amid the stock market’s down year, pension funds need to shift more than $60 billion into stocks before the end of the month, according to analysts at Wells Fargo......»»

Category: topSource: marketwatchDec 31st, 2018

This investment cost Apple $9 billion in 2018

Many large companies, including Apple, Wells Fargo and Citigroup, have used much of the windfall from the 2017 tax overhaul to buy back shares. But the recent plunge in stock prices has made that look like a bad idea......»»

Category: topSource: moneycentralDec 28th, 2018

This investment cost Apple $9 billion in 2018

Many large companies, including Apple, Wells Fargo and Citigroup, have used much of the windfall from the 2017 tax overhaul to buy back shares. But the recent plunge in stock prices has made that look like a bad idea......»»

Category: topSource: moneycentralDec 28th, 2018